CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers

Published:2020-09-08 Issue:11 Volume:29 Page:1295-1308
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Jiao Ying¹,Yi Ming¹,Xu Linping²,Chu Qian¹,Yan Yongxiang³,Luo Suxia²,Wu Kongming¹²

Affiliation:

1. Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

2. Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

3. R & D Department, Wuhan YZY Biopharma Co., Ltd, Wuhan, China

Funder

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2020.1814253

Reference142 articles.

1. SnapShot: Multiple Myeloma

2. Multiple myeloma epidemiology and survival: A unique malignancy

3. Cancer statistics, 2020

4. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

5. Building better monoclonal antibody-based therapeutics

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CT-based radiomics predicts CD38 expression and indirectly reflects clinical prognosis in epithelial ovarian cancer;Heliyon;2024-06

2. An overview of multiple myeloma: A monoclonal plasma cell malignancy’s diagnosis, management, and treatment modalities;Saudi Journal of Biological Sciences;2024-02

3. m6A methyltransferase METTL3 facilitates multiple myeloma cell growth through the m6A modification of BZW2;Annals of Hematology;2023-05-24

4. Immunotherapy-based combinations in metastatic NSCLC;Cancer Treatment Reviews;2023-05

5. The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives;Experimental Hematology & Oncology;2023-01-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3